Symbols / CARM $0.00 +0.00% Carisma Therapeutics, Inc.

Healthcare • Biotechnology • United States • PNK
CARM Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country PNK · United States
Market Cap 41.84K
Enterprise Value -2.00M
Income 8.04M
Sales 52.63M
FCF (ttm) 13.05M
Book/sh -0.02
Cash/sh 0.07
Employees 46
Insider 10d —
IPO Feb 06, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 0.01
Forward P/E -0.00
PEG —
P/S 0.00
P/B -0.05
P/C —
EV/EBITDA -0.14
EV/Sales -0.04
Quick Ratio 0.65
Current Ratio 0.86
Debt/Eq —
LT Debt/Eq —
EPS (ttm) 0.19
EPS next Y -0.91
EPS Growth —
Revenue Growth 12.37%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-08-07
Earnings (prior) 2025-08-07
ROA 33.03%
ROE —
ROIC —
Gross Margin 48.03%
Oper. Margin 96.83%
Profit Margin 15.28%
Shs Outstand 41.85M
Shs Float 30.14M
Insider Own 26.56%
Instit Own 11.00%
Short Float 3.57%
Short Ratio 0.06
Short Interest 1.29M
52W High 1.27
vs 52W High -99.92%
52W Low 0.00
vs 52W Low 0.00%
Beta 3.50
Impl. Vol. —
Rel Volume 0.12
Avg Volume 83.25K
Volume 10.30K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.00
Price $0.00
Change 0.00%
About

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$5.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-08-08 main D. Boral Capital Buy → Buy $1
2025-04-01 main D. Boral Capital Buy → Buy $1
2025-01-17 main D. Boral Capital Buy → Buy $12
2025-01-13 main D. Boral Capital Buy → Buy $12
2024-12-16 down HC Wainwright & Co. Buy → Neutral —
2024-12-12 main D. Boral Capital Buy → Buy $12
2024-12-12 down Baird Outperform → Neutral $1
2024-12-11 down Evercore ISI Group Outperform → In-Line $1
2024-12-10 down BTIG Buy → Neutral —
2024-12-09 main D. Boral Capital Buy → Buy $12
2024-11-25 main HC Wainwright & Co. Buy → Buy $5
2024-11-18 main D. Boral Capital Buy → Buy $24
2024-11-11 main D. Boral Capital Buy → Buy $24
2024-11-07 main EF Hutton Buy → Buy $24
2024-10-30 init EF Hutton — → Buy $24
2024-06-28 reit HC Wainwright & Co. Buy → Buy $8
2024-06-26 reit HC Wainwright & Co. Buy → Buy $8
2024-05-17 reit HC Wainwright & Co. Buy → Buy $8
2024-05-10 main HC Wainwright & Co. Buy → Buy $8
2024-04-11 init BTIG — → Buy $6
News
RSS: Latest CARM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-07 KLICHINSKY MICHAEL Officer — 56,982 $0.25 $14,485
2025-10-07 KLICHINSKY MICHAEL Officer — 56,982 $0.11 $6,268
2025-10-03 KLICHINSKY MICHAEL Officer — 484,347 $0.25 $124,343
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
19.63
+31.59%
14.92
+51.71%
9.83
0.00
Operating Revenue
19.63
+31.59%
14.92
+51.71%
9.83
0.00
Operating Expense
81.81
-21.07%
103.65
+57.05%
66.00
+61.78%
40.79
Research And Development
59.67
-19.50%
74.12
+30.92%
56.62
+64.65%
34.39
Selling General And Administration
22.14
-25.02%
29.52
+214.83%
9.38
+46.37%
6.41
General And Administrative Expense
22.14
-25.02%
29.52
+214.83%
9.38
+46.37%
6.41
Salaries And Wages
9.75
-8.65%
10.67
+214.13%
3.40
+38.88%
2.45
Other Gand A
11.04
-30.85%
15.96
+176.67%
5.77
+45.67%
3.96
Total Expenses
81.81
-21.07%
103.65
+57.05%
66.00
+61.78%
40.79
Operating Income
-62.18
+29.92%
-88.73
-57.99%
-56.16
-37.67%
-40.79
Total Operating Income As Reported
-62.18
+29.92%
-88.73
-57.99%
-56.16
-37.67%
-40.79
EBITDA
-58.83
+31.51%
-85.89
-52.87%
-56.19
-40.08%
-40.11
Normalized EBITDA
-58.83
+31.45%
-85.81
-58.12%
-54.27
-35.29%
-40.11
Reconciled Depreciation
3.35
+18.22%
2.84
+49.87%
1.89
+177.57%
0.68
EBIT
-62.18
+29.92%
-88.73
-52.77%
-58.08
-42.38%
-40.79
Total Unusual Items
—
-0.08
+95.62%
-1.92
—
Total Unusual Items Excluding Goodwill
—
-0.08
+95.62%
-1.92
—
Net Income
-60.48
+30.39%
-86.88
-41.90%
-61.23
-50.12%
-40.78
Pretax Income
-60.48
+30.39%
-86.88
-41.90%
-61.23
-50.12%
-40.78
Net Non Operating Interest Income Expense
1.70
-12.09%
1.94
+161.56%
-3.15
-31550.00%
0.01
Interest Expense Non Operating
—
—
3.15
—
Net Interest Income
1.70
-12.09%
1.94
+161.56%
-3.15
-31550.00%
0.01
Interest Expense
—
—
3.15
—
Interest Income Non Operating
1.70
-12.09%
1.94
—
0.01
Interest Income
1.70
-12.09%
1.94
—
0.01
Other Income Expense
—
-0.08
+95.62%
-1.92
—
Gain On Sale Of Security
—
-0.08
+95.62%
-1.92
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-60.48
+30.39%
-86.88
-41.90%
-61.23
-50.12%
-40.78
Net Income From Continuing Operation Net Minority Interest
-60.48
+30.39%
-86.88
-41.90%
-61.23
-50.12%
-40.78
Net Income From Continuing And Discontinued Operation
-60.48
+30.39%
-86.88
-41.90%
-61.23
-50.12%
-40.78
Net Income Continuous Operations
-60.48
+30.39%
-86.88
-41.90%
-61.23
-50.12%
-40.78
Normalized Income
-60.48
+30.32%
-86.80
-46.35%
-59.31
-45.42%
-40.78
Net Income Common Stockholders
-60.48
+30.39%
-86.88
-41.90%
-61.23
-50.12%
-40.78
Diluted EPS
-1.46
+43.63%
-2.59
-70.29%
-1.52
-50.12%
-1.01
Basic EPS
-1.46
+43.63%
-2.59
-70.29%
-1.52
-50.12%
-1.01
Basic Average Shares
41.46
+23.66%
33.52
-16.72%
40.25
+0.00%
40.25
Diluted Average Shares
41.46
+23.66%
33.52
-16.72%
40.25
+0.00%
40.25
Diluted NI Availto Com Stockholders
-60.48
+30.39%
-86.88
-41.90%
-61.23
-50.12%
-40.78
Insurance And Claims
1.35
-53.25%
2.89
+1269.67%
0.21
—
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Assets
30.46
-65.99%
89.55
+24.12%
72.15
+103.54%
35.45
Current Assets
23.82
-70.39%
80.47
+47.40%
54.59
+83.28%
29.79
Cash Cash Equivalents And Short Term Investments
17.91
-76.92%
77.61
+49.25%
52.00
+82.12%
28.55
Cash And Cash Equivalents
17.91
-76.92%
77.61
+220.76%
24.19
-15.26%
28.55
Other Short Term Investments
—
0.00
-100.00%
27.80
—
Prepaid Assets
—
—
—
1.24
Other Current Assets
5.92
+106.42%
2.87
+10.40%
2.60
+110.20%
1.24
Total Non Current Assets
6.63
-26.97%
9.08
-48.28%
17.56
+210.10%
5.66
Net PPE
6.42
-28.11%
8.94
-33.55%
13.45
+137.51%
5.66
Gross PPE
14.31
-5.14%
15.09
-10.00%
16.76
+136.65%
7.08
Accumulated Depreciation
-7.89
-28.22%
-6.15
-85.61%
-3.31
-133.22%
-1.42
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.78
-33.76%
1.17
-11.96%
1.33
+176.30%
0.48
Construction In Progress
0.00
-100.00%
0.01
+0.00%
0.01
+0.00%
0.01
Other Properties
13.20
-2.71%
13.56
-10.06%
15.08
+140.43%
6.27
Leases
0.34
+0.00%
0.34
+0.00%
0.34
+7.26%
0.32
Non Current Deferred Assets
0.21
+42.47%
0.15
-96.45%
4.11
—
Total Liabilities Net Minority Interest
58.37
-7.39%
63.02
-70.66%
214.82
+2179.29%
9.43
Current Liabilities
16.05
+0.92%
15.91
-19.13%
19.67
+155.75%
7.69
Payables And Accrued Expenses
4.65
-45.26%
8.49
-8.46%
9.28
+36.61%
6.79
Payables
2.08
-47.09%
3.93
+127.60%
1.73
-25.58%
2.32
Accounts Payable
2.08
-47.09%
3.93
+127.60%
1.73
-25.58%
2.32
Current Accrued Expenses
2.57
-43.69%
4.56
-39.59%
7.55
+68.91%
4.47
Pensionand Other Post Retirement Benefit Plans Current
4.88
+57.39%
3.10
+10.36%
2.81
—
Current Debt And Capital Lease Obligation
1.74
-10.23%
1.94
-57.93%
4.60
+412.14%
0.90
Current Capital Lease Obligation
1.74
-10.23%
1.94
-57.93%
4.60
+412.14%
0.90
Current Deferred Liabilities
3.73
+163.91%
1.41
-42.54%
2.46
—
Current Deferred Revenue
3.73
+163.91%
1.41
-42.54%
2.46
—
Other Current Liabilities
1.06
+9.84%
0.96
+84.51%
0.52
—
Total Non Current Liabilities Net Minority Interest
42.31
-10.19%
47.11
-75.86%
195.15
+11154.50%
1.73
Long Term Debt And Capital Lease Obligation
0.74
-37.37%
1.19
-96.66%
35.56
+1951.04%
1.73
Long Term Debt
—
—
33.72
—
Long Term Capital Lease Obligation
0.74
-37.37%
1.19
-35.71%
1.85
+6.57%
1.73
Non Current Deferred Liabilities
41.25
-8.33%
45.00
+0.00%
45.00
—
Non Current Deferred Revenue
41.25
-8.33%
45.00
+0.00%
45.00
—
Other Non Current Liabilities
0.32
-65.66%
0.93
-11.05%
1.04
—
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
107.81
—
Stockholders Equity
-27.91
-205.19%
26.53
+116.89%
-157.06
-1450.63%
11.63
Common Stock Equity
-27.91
-205.19%
26.53
+116.89%
-157.06
-63.30%
-96.18
Capital Stock
0.04
+2.50%
0.04
+1900.00%
0.00
-100.00%
107.81
Common Stock
0.04
+2.50%
0.04
+1900.00%
0.00
0.00
Preferred Stock
0.00
0.00
0.00
-100.00%
107.81
Share Issued
41.75
+2.81%
40.61
+0.88%
40.25
+0.00%
40.25
Ordinary Shares Number
41.75
+2.81%
40.61
+0.88%
40.25
+0.00%
40.25
Additional Paid In Capital
277.63
+2.22%
271.59
+22589.56%
1.20
+46.33%
0.82
Retained Earnings
-305.58
-24.67%
-245.10
-54.91%
-158.22
-63.12%
-97.00
Gains Losses Not Affecting Retained Earnings
—
0.00
+100.00%
-0.04
—
Minority Interest
—
0.00
-100.00%
14.39
+0.00%
14.39
Other Equity Adjustments
—
—
-0.04
—
Total Equity Gross Minority Interest
-27.91
-205.19%
26.53
+118.60%
-142.67
-648.22%
26.02
Total Capitalization
-27.91
-205.19%
26.53
+121.51%
-123.35
-1160.69%
11.63
Working Capital
7.77
-87.97%
64.56
+84.88%
34.92
+58.05%
22.09
Invested Capital
-27.91
-205.19%
26.53
+121.51%
-123.35
-28.25%
-96.18
Total Debt
2.48
-20.56%
3.12
-92.22%
40.16
+1425.99%
2.63
Net Debt
—
—
9.52
—
Capital Lease Obligations
2.48
-20.56%
3.12
-51.56%
6.45
+144.95%
2.63
Net Tangible Assets
-27.91
-205.19%
26.53
+116.89%
-157.06
-1450.63%
11.63
Tangible Book Value
-27.91
-205.19%
26.53
+116.89%
-157.06
-63.30%
-96.18
Derivative Product Liabilities
—
0.00
-100.00%
5.74
—
Interest Payable
—
0.00
-100.00%
1.13
—
Preferred Stock Equity
—
—
—
107.81
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-59.92
+26.19%
-81.18
-1486.73%
-5.12
+86.29%
-37.33
Cash Flow From Continuing Operating Activities
-59.92
+26.19%
-81.18
-1486.73%
-5.12
+86.29%
-37.33
Net Income From Continuing Operations
-60.48
+30.39%
-86.88
-41.90%
-61.23
-50.12%
-40.78
Depreciation Amortization Depletion
3.35
+18.22%
2.84
+49.87%
1.89
+177.57%
0.68
Depreciation And Amortization
3.35
+18.22%
2.84
+49.87%
1.89
+177.57%
0.68
Other Non Cash Items
5.18
-24.38%
6.85
+0.34%
6.83
+718.59%
0.83
Stock Based Compensation
3.65
+57.56%
2.32
+742.18%
0.28
-42.59%
0.48
Asset Impairment Charge
0.36
0.00
—
—
Operating Gains Losses
-0.03
+78.85%
-0.16
-108.13%
1.92
—
Gain Loss On Investment Securities
—
-0.32
-116.41%
1.92
—
Gain Loss On Sale Of PPE
-0.03
-120.75%
0.16
0.00
—
Change In Working Capital
-11.95
-119.87%
-5.44
-112.03%
45.20
+2993.50%
1.46
Change In Prepaid Assets
-3.12
-398.28%
1.05
+176.86%
-1.36
-637.94%
0.25
Change In Payables And Accrued Expense
-2.06
-191.67%
-0.71
-118.84%
3.76
+85.90%
2.02
Change In Accrued Expense
-0.21
+92.65%
-2.90
-168.53%
4.23
+41.24%
3.00
Change In Payable
-1.85
-184.53%
2.19
+563.21%
-0.47
+51.44%
-0.97
Change In Account Payable
-1.85
-184.53%
2.19
+563.21%
-0.47
+51.44%
-0.97
Change In Other Working Capital
-1.43
-37.09%
-1.05
-102.20%
47.46
—
Change In Other Current Liabilities
-5.33
-12.80%
-4.73
-1.48%
-4.66
-473.06%
-0.81
Investing Cash Flow
-0.12
-100.17%
72.41
+322.38%
-32.56
-1640.25%
-1.87
Cash Flow From Continuing Investing Activities
-0.12
-100.17%
72.41
+322.38%
-32.56
-1640.25%
-1.87
Net PPE Purchase And Sale
-0.12
+89.13%
-1.13
+75.71%
-4.66
-149.06%
-1.87
Purchase Of PPE
-0.12
+89.13%
-1.13
+75.71%
-4.66
-149.06%
-1.87
Capital Expenditure
-0.12
+89.13%
-1.13
+75.71%
-4.66
-149.06%
-1.87
Net Investment Purchase And Sale
0.00
-100.00%
73.54
+363.58%
-27.90
—
Purchase Of Investment
0.00
+100.00%
-34.46
+62.09%
-90.90
—
Sale Of Investment
0.00
-100.00%
108.00
+71.43%
63.00
—
Financing Cash Flow
0.34
-99.45%
62.18
+86.62%
33.32
+108.74%
15.96
Cash Flow From Continuing Financing Activities
0.34
-99.45%
62.18
+86.62%
33.32
+108.74%
15.96
Net Issuance Payments Of Debt
-1.43
-9.84%
-1.30
-103.81%
34.13
—
Issuance Of Debt
—
0.00
-100.00%
35.00
—
Repayment Of Debt
-1.43
-9.84%
-1.30
-50.40%
-0.86
—
Long Term Debt Issuance
—
0.00
-100.00%
35.00
—
Long Term Debt Payments
-1.43
-9.84%
-1.30
-50.40%
-0.86
—
Net Long Term Debt Issuance
-1.43
-9.84%
-1.30
-103.81%
34.13
—
Net Common Stock Issuance
2.39
-92.34%
31.24
0.00
—
Proceeds From Stock Option Exercised
0.00
-97.86%
0.19
+76.42%
0.11
0.00
Net Other Financing Charges
-0.62
-101.94%
32.06
+3576.90%
-0.92
-151.91%
-0.37
Changes In Cash
-59.70
-211.77%
53.41
+1325.87%
-4.36
+81.25%
-23.24
Beginning Cash Position
77.61
+220.76%
24.19
-15.26%
28.55
-44.87%
51.79
End Cash Position
17.91
-76.92%
77.61
+220.76%
24.19
-15.26%
28.55
Free Cash Flow
-60.04
+27.06%
-82.31
-741.95%
-9.78
+75.06%
-39.20
Interest Paid Supplemental Data
0.19
-45.45%
0.35
+259.18%
0.10
—
Amortization Of Securities
0.00
+100.00%
-0.71
0.00
—
Common Stock Issuance
2.39
-92.34%
31.24
0.00
—
Issuance Of Capital Stock
2.39
-92.34%
31.24
0.00
-100.00%
16.33
Net Preferred Stock Issuance
—
—
—
16.33
Preferred Stock Issuance
—
—
—
16.33
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category